Company intelligence / Profile preview
Tego Science
- Ownership
- Private
- Development stage
- Other
Overview
Tego Science has commercialized several autologous/allogeneic cell therapy products for skin regeneration—such as Holoderm®, Kaloderm®, Neoderm®, Rosmir®—with regulatory approvals in South Korea and exports to Japan. The company’s core technologies enable the cultivation of keratinocyte stem cells that retain their regenerative properties after transplantation. Clinical programs include advanced wound healing applications such as diabetic foot ulcers and burns. Recent pipeline candidates are in Phase II trials. The company also provides contract research services related to analytical testing/tissue staining.
- Therapeutic areas
- EndocrinologyDermatology
- Modalities
- Cell therapy (autologous and allogeneic)Tissue engineering (cultured skin substitutes)Regenerative medicine
- Industry
- Biotech
Drug pipeline
14 assets13 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Tego Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tego Science.